Acepromazine in dogs still warrants careful case selection
Bottom line
Acepromazine remains a familiar drug in canine practice, but the latest reminder from Whole Dog Journal underscores a longstanding clinical tension: acepromazine can be useful for sedation and restraint, yet it carries meaningful limits and risks that make case selection critical. The FDA-approved PromAce label for dogs warns that acepromazine can cause rare but serious idiosyncratic reactions, including aggression, biting, chewing, and nervousness, and notes that epinephrine is contraindicated for acepromazine-associated hypotension. Merck Veterinary Manual also highlights hypotension, ataxia, paradoxical excitation, and behavioral disinhibition, while behavior-focused sources continue to stress that acepromazine is a sedative, not a true anxiolytic. (dailymed.nlm.nih.gov)
Why it matters: For veterinary professionals, the caution is less about a new safety signal than about appropriate use. In dogs presented for noise aversion, travel stress, or veterinary visit anxiety, acepromazine may quiet outward behavior without addressing underlying fear, which can mask distress and, in some patients, worsen disinhibition or paradoxical responses. Breed and patient factors also matter: authoritative references advise extra caution in brachycephalic dogs because of vagal effects, and reduced dosing or heightened monitoring in dogs with MDR1-related sensitivity, including some collies and sheepdogs. Blood pressure monitoring is especially relevant in patients with cardiovascular compromise, dehydration, concurrent hypotensive drugs, or peri-anesthetic risk. (merckvetmanual.com)
What to watch: Expect continued emphasis on individualized sedative plans, especially as Fear Free and behavior-guided protocols keep pushing clinicians toward agents with clearer anxiolytic effects for outpatient stress events and pre-visit care. (vin.com)
Key facts
- Drug
- Acepromazine
- Brand
- PromAce
- Species
- Dogs only
- FDA label update
- March 6, 2025
- Use
- Sedation and restraint
- Key risks
- Rare idiosyncratic reactions, hypotension, ataxia, paradoxical excitation, and behavioral disinhibition
- Contraindication
- Epinephrine for acepromazine-associated hypotension
- Caution groups
- Brachycephalic dogs, dogs with MDR1-related sensitivity, and dogs with cardiovascular compromise or dehydration
- Behavior note
- Sedative, not a true anxiolytic
Acepromazine is back in the spotlight with a consumer-facing caution from Whole Dog Journal, but the underlying message will sound familiar to many clinicians: this legacy phenothiazine still has a place in canine medicine, though its use demands careful attention to indication, patient selection, and monitoring. Current reference sources describe acepromazine as a tranquilizer and sedative with predictable utility for restraint and peri-procedural calming, but they also point to adverse effects and clinical limitations that can make it a poor fit for some dogs and scenarios. (merckvetmanual.com)
That tension has followed acepromazine for years. The FDA-approved DailyMed label for PromAce, updated March 6, 2025, states that the drug is approved for use in dogs only and restricted to use by or on the order of a licensed veterinarian. The label also warns that, because acepromazine is a phenothiazine derivative metabolized by the liver, it should be used cautiously in dogs with prior liver dysfunction or leukopenia, and that epinephrine is contraindicated if acute hypotension occurs after administration. (dailymed.nlm.nih.gov)
Beyond the label, the broader veterinary literature helps explain why caution persists. Merck Veterinary Manual notes that acepromazine causes vasodilation through alpha-1 blockade and can produce sedation within about 10 minutes in small animals, with effects lasting roughly four to six hours. The same source lists sedation, ataxia, involuntary muscle movements, dystonia, disinhibition, and paradoxical excitation among reported adverse effects, and advises caution in brachycephalic breeds because excessive vagal tone can be particularly severe. (merckvetmanual.com)
Behavior and handling specialists have drawn an equally important distinction: acepromazine may sedate a dog without relieving fear. Proceedings and educational materials from VIN, WSAVA, and Fear Free consistently describe acepromazine as not being used as an anxiolytic, or as having no meaningful anxiolytic effect when used alone. In practical terms, that means a dog may appear quieter while still experiencing distress, a concern that matters in noise phobia, travel stress, and pre-visit pharmaceutical planning. Veterinary Partner also notes that acepromazine is not recommended for air travel, citing concerns that sedation can impair a dog’s ability to respond to stressful conditions during transport. (vin.com)
Patient-specific risk remains central to safe use. VCA and Washington State University resources point to greater sensitivity in dogs with the MDR1 mutation, with lower doses advised and specialist dosing support recommended for affected dogs. VCA also flags prolonged or exaggerated effects in some collies, sheepdogs, giant breeds, greyhounds, and Boxers from UK-bred lines. Meanwhile, Merck and anesthesia references emphasize hemodynamic caution, particularly in dogs with cardiovascular instability, hypovolemia, dehydration, or concurrent exposure to other hypotensive agents. (vcahospitals.com)
Why it matters: For veterinary teams, this is a reminder to match the drug to the goal. If the objective is restraint, peri-anesthetic sedation, or adjunctive calming in a controlled setting, acepromazine may still be appropriate. If the objective is reducing fear, panic, or situational anxiety, many contemporary behavior-oriented sources favor other options, including trazodone, gabapentin, benzodiazepines, clonidine, or dexmedetomidine-based approaches, depending on the case. The deeper issue is clinical visibility: sedation without anxiolysis can make a patient look improved while masking pain, fear, or escalating stress, which has implications for handling safety, welfare, and pet parent counseling. (vin.com)
Expert and industry commentary broadly aligns on that point. Lisa Radosta, DVM, DACVB, in WSAVA proceedings hosted by VIN, states plainly that acepromazine is used as a sedative and “is not used as an anxiolytic,” while Fear Free educational materials similarly advise against using acepromazine alone as an oral pre-visit pharmaceutical. Those views don’t amount to a blanket rejection of the drug, but they do reflect a shift in how many clinicians think about fear, stress, and patient welfare in outpatient medicine. (vin.com)
What to watch: The next development is unlikely to be a regulatory overhaul so much as a continued practice shift. Expect more scrutiny of legacy sedatives in outpatient behavioral use, more emphasis on genotype- and comorbidity-aware prescribing, and more demand from pet parents for protocols that reduce both visible reactivity and underlying distress. (dailymed.nlm.nih.gov)